stockrow
Friday 6 November 2026
Export AMLX’s income statement to Excel — free account
Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
27.79
1.61
−5.48%
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Revenue growth
Amylyx Pharmaceuticals, Inc.'s revenue growth over the twelve months to 31 December 2024 was −77.1%. That is below the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2024 | −77.1% | (1,690.00) |
| FY2023 | 1,612.9% | (6,087.06) |
| FY2022 | 7,700.0% | 7,756.15 |
| FY2021 | −56.2% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Dec 2024 | −100.6% | (1.02) |
| Sep 2024 | −99.6% | 1.45 |
| Jun 2024 | −101.0% | (125.14) |
| Mar 2024 | 24.1% | (371.44) |
| 3 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LQDA Liquidia Corporation compare | 2,233.7% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 245.2% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | 16.4% |
| PBH Prestige Consumer Healthcare Inc. compare | 5.10% |
| PRGO Perrigo Company plc compare | −4.47% |
| TRLV Trulieve Cannabis Corp. compare | −9.09% |
| AMLX Amylyx Pharmaceuticals, Inc. | −77.1% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement